Findings

What do systematic reviews say?

7 questions · 7 findings · 1 reviews · Headline outcomes only

No studies found 2 · 28.6%GRADE not reported 0 · 0%Very low 0 · 0%Low 4 · 57.1%Moderate 1 · 14.3%High 0 · 0%

Time from beginning of treatment until death or full‐time ventilation · children with SMA type II

1 finding from 1 review

Drug treatment for spinal muscular atrophy types II and III 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 107 participants
Low

Adverse events related to treatment · children with SMA type II

Oral phenylbutyrate probably leads to higher adverse events related to treatment compared with placebo (moderate certainty).

1 finding from 1 review

Drug treatment for spinal muscular atrophy types II and III 2020 · Cochrane Headline outcomes only
RR 3.1 [1.25, 7.84]
1 study · 107 participants
Moderate

Change in disability score · children with SMA type II

1 finding from 1 review

Drug treatment for spinal muscular atrophy types II and III 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 90 participants
Low

Muscle strength · children with SMA type II

1 finding from 1 review

Drug treatment for spinal muscular atrophy types II and III 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 70 participants
Low

Acquiring the ability to stand or walk · children with SMA type II

The review found no eligible studies for this question.

1 finding from 1 review

Drug treatment for spinal muscular atrophy types II and III 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Change in quality of life · children with SMA type II

The review found no eligible studies for this question.

1 finding from 1 review

Drug treatment for spinal muscular atrophy types II and III 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Change in pulmonary function · children with SMA type II

1 finding from 1 review

Drug treatment for spinal muscular atrophy types II and III 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 67 participants
Low